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Abstract (272 words) 
Purpose: We examined estrogen receptor (ER) mRNA expression and molecular 
subtypes in stage I-III breast cancers that are progesterone receptor (PR) positive but ER 
and HER2 negative by immunohistochemistry (IHC) or fluorescent in situ 
hybridization.    
Patients and Methods: The ER, PR and HER2 status was determined by IHC as part of 
routine clinical assessment (N=501). Gene expression profiling was done with the 
Affymetrix U133A gene chip. We compared expressions of ESR1, MKI67 mRNA, 
distribution of molecular subtypes by the PAM50 classifier, the sensitivity to endocrine 
therapy index and the DLDA30 chemotherapy response predictor signature among 
ER/PR positive (n=223), ER positive/PR negative (n=73), ER negative/PR positive 
(n=20), and triple-negative (n=185) cancers. All patients received neoadjuvant 
chemotherapy with an anthracycline and taxane and had adjuvant endocrine therapy 
only if ER or PR > 10% positive.  
Results: ESR1 expression was high in 25% of ER negative/PR positive, in 79% of ER 
positive/PR negative, in 96% of ER/PR positive, and in 12% of triple negative cancers 
by IHC. The average MKI67 expression was significantly higher in the ER negative/PR 
positive and triple-negative cohorts. Among the ER negative/PR positive patients, 15% 
were luminal A, 5% Luminal B, and 65% basal like. The relapse free survival rate of ER 
negative/PR positive patients was equivalent to ER positive cancers and better than the 
triple-negative cohort.    
Conclusion: Only 20-25% of the ER negative/PR positive tumors show molecular 
features of ER positive cancers. In this rare subset of patients (i) a second RNA based 
assessment may help identifying the minority of ESR1 mRNA-positive, luminal type 
cancers and (ii) the safest clinical approach may be to consider both adjuvant endocrine 
and chemotherapy. 
  
 (1,483 words) 
Introduction 
Estrogen (ER) and progesterone receptor (PR) are routinely assessed in all 
primary breast cancers by immunohistochemistry (IHC) [1] and adjuvant endocrine 
therapy is recommended if either of these receptors is positive (i.e. > 1% by IHC) [2-4]. 
The expression of PR is activated by ERα via an estrogen responsive 
element–containing gene promoter. Therefore, it has been proposed that PR expression 
indicates the presence of functional ERα[5] and loss of PR expression potentially 
defines a subpopulation of patients with inferior benefit from tamoxifen compared to 
PR receptor persisted cancers.[6] In this model, the existence of ER negative/PR 
positive cancers represents an enigma. It has even been suggested that the majority of 
ER negative but PR positive cancers may represent false negative IHC results for 
ER.[7] After reevaluation of the tumor slides and control tissues, most cases of ER 
negative/PR positive cases changed their original phenotype. [7] The more, Hefti et al 
also reported that ER negative/PR positive cases showed no significant reproducibility 
by integrated gene expression microarray and clinico-pathological data.[8] 
The prognostic value of PR expression independent of any endocrine therapy 
and its interaction with benefit from endocrine therapy in ER positive cancers has been 
documented by several studies. In ER positive cancers, patients with PR positive 
disease have lower risks of recurrence and mortality compared to PR negative cancers 
both with and without adjuvant endocrine therapy.[9] Prat et al reported that PR 
expression adds to the prognostic value of luminal A classification and can further 
sub-stratify patients among luminal cancers.[10] Viale et al also showed that PR 
expression predicts for adjuvant chemotherapy benefit among pre- and peri-menopausal 
but not post-menopausal patients with ER positive cancers.[11] The predictive and 
prognostic value of PR expression in ER negative cancers is much less understood, 
mostly because of the rarity of this disease subset. 
Approximately 3 % of all breast cancers are ER negative and PR positive.[12] 
Some data suggests that cancers may not significantly benefit from adjuvant endocrine 
therapy.[9]  In 2010, joint guidelines by the American Society of Clinical Oncology 
(ASCO) and the American College of Pathologists recommended that hormone receptor 
(HR) status should be considered positive if 1% or more of tumor cells demonstrate 
positive nuclear staining of either ER or PR with an IHC assay[1]. Historically, many 
investigators and clinicians considered 10% or greater IHC staining as the threshold for 
defining HR positive status and therefore eligibility for endocrine therapy. We have 
previously showed that the majority of ER borderline, 1-9% IHC positive, cases had 
molecular features similar to ER negative cancers.[13]         
In the current study, we examined ESR1 mRNA expression and molecular 
subtype distribution among ER negative but PR positive cancers and assessed hormone 
and chemotherapy sensitivity markers in these cancers.[14, 15] The purpose of these 
analyses was to determine whether ER negative/PR positive cancers show the same 
global gene expression patterns and molecular subtypes as ER positive cancers do or if 
they are more similar to ER negative cancers. 
  
Patients and Methods   
Five hundred one patients were included in this study who participated in a 
prospective institutional review board approved biomarker discovery study at MD 
Anderson Cancer Center in Houston, TX and signed informed consent for molecular 
analysis of their pretreatment cancer biopsy and had routine marker and gene expression 
data available. The ER, PR and HER2 status was assessed on diagnostic core needle 
biopsies in the routine pathology laboratory. Clinical ER status was determined by IHC 
using the ERalfa antibody 6F11 (Novocastra/Vector Laboratories, Burlingame, CA) and 
PR status was determined by using the antibody 1A6 (Novacastra Laboratories Ltd., 
Burlingame, CA). The cut-off for ER or PR positivity for this analysis was >1% tumor 
cells with nuclear staining. HER2 status had been assessed either by fluorescence in situ 
hybridization or by IHC (Dako North America, Inc., Carpinteria, CA, USA). HER2 
positivity had been defined as either HER2 gene amplification if immunohistochemical 
score was 2+ or an immunohistochemical score of 3+. Two hundred and twenty three 
patients were ER and PR positive, 73 were ER positive but PR negative, 20 were ER 
negative but PR positive and 185 were ER and PR negative. All patients received 
neoadjuvant chemotherapy containing a taxane and anthracycline based regimen, and 
patients with ER or PR positive tumors defined as ≥ 10% staining also received 
adjuvant endocrine therapy. 
Gene expression profiling with Affymetrix U133 gene chips were performed 
on fine needle aspirations obtained before any therapy and independent of the diagnostic 
core needle biopsy used for routine ER, PR and HER2 determination. Gene expression 
data is available under GEO (Gene Expression Omnibus) accession number GSE 25066 
and methods were described in a previous a publication.[16] Expression data were 
normalized with the MAS5 algorithm, mean centered to 600 and log2 transformed. 
Probe set 205225_at was used as the measure of ESR1 mRNA expression, and a 
log2-transformed expression value of ≥ 10.18 was considered as ER positive by mRNA 
based on of a threshold established and validated in previous publications.[13, 17, 18] 
We also assessed PR mRNA expression by probe set 208305_at and Ki67 (MKI67) 
expression by probe set 212021_s_at. An ER metagene was calculated as the average 
log2 transformed expression values of ESR1, PR, BCL2 and SCUBE2 as measure of 
endocrine sensitivity (based on OncotypeDX ER score). The PAM50 classifier, the 
sensitivity to endocrine therapy (SET) index and the DLDA30 chemotherapy response 
predictor signature were also applied to the data as previously described.[14-16, 19] The 
Wilcoxon test was used to determine statistical significance of gene expression 
differences between IHC subsets. We also plotted survival curves with the log-rank test 
by ER and PR status based on IHC. Statistical analyses were performed using the 
BRB-ArrayTools v 4.1.0 (http://linus.nci.nih.gov/BRB-ArrayTools.html) and the R 
software v 2.7.2 (http://www.r-project.org). Two sided p values< 0.05 were considered 
statistically significant. 
 
Results 
Patients characteristics are shown in Table 1. Sixty three percent of tumors 
were hormone receptor (HR) positive (ER and/or PR ≥ 1%[1]) by IHC. Among the IHC 
ER negative/PR positive, ER positive/PR negative, ER/PR positive, and ER/PR 
negative patients, 25% (= 5/20), 79% (= 58/73), 96% (= 213/223) and 12% (= 22/185) 
were also positive by ESR1 mRNA expression, respectively (Table 2). Among the ER 
negative/PR positive patients, 15% were luminal A, 5% were Luminal B, and 65% were 
basal like; among the ER positive/PR negative patients, 59% were luminal type (Table 
2).  An additional 22 patients who were IHC ER/PR negative (12% of ER/PR negative 
cases) were positive by ESR1 mRNA gene expression and may be considered as false 
negative IHC results (Table 2).  The Sensitivity to Endocrine Therapy (SET) index 
assigned low sensitivity to 90% of the ER negative/PR positive cancers (Table 2).  The 
chemotherapy sensitivity gene score, DLDA30, predicted high chemotherapy sensitivity 
for 60% of the ER negative/PR positive patients and for 21% of ER positive/PR 
negative patients (Table 2).  Only 5 % (12/233) of the ER/PR positive patients were 
assigned to the high chemotherapy sensitivity group. 
Figure 1 shows the relationship between ER/PR protein expression and ESR1, 
PR and MKI67 mRNA gene expression and the ER metagene. The associations between 
IHC ER/PR subtypes and the mRNA gene expression level (ESR1, PR and ER-related 
genes) were similar and consistent, indicating that they were highly correlated each 
other. The majority of the ER negative/PR positive patients (75%) showed low ESR1 
mRNA, low PR and low ER metagene expression, and were assigned to ER negative 
status by these metrics.  In contrast the majority of ER positive/PR negative cases 
showed high ESR1 and ER metagene expression that were consistent with ER positive 
status. The average MKI67 expression was also significantly higher in the ER 
negative/PR positive and ER/PR negative cancers compared to other subtypes. (Fig. 1)     
Among the ER negative/PR positive, ER positive/PR negative, ER/PR positive 
and ER/PR negative, 40% (8/20), 16% (12/73), 8% (18/223) and 32% (60/185) 
achieved pathological complete response that was defined as absence of any residual 
invasive cancer in the breast and absence of any metastatic cells in the regional lymph 
nodes after neoadjuvant chemotherapy. The relapse free survival rate of ER negative/PR 
positive patients who received chemotherapy (and nine of them received additional 
adjuvant endocrine therapy) was equivalent to ER/PR positive or ER positive/PR 
negative cases that received both endocrine and chemotherapy, and significantly better 
than the relapse free survival of ER/PR negative cancers. (Fig. 2) 
 
Discussions 
ER negative/PR positive breast cancers are rare; this and previous studies 
indicate that approximately 3 to 4% if all breast cancers fall into this category.[12] 
Because it represents a rare receptor subtype, it is unlikely that a prospective clinical 
trial would ever be conducted to define the optimal adjuvant treatment strategy for this 
disease. ER negative/PR positive status may arise from testing artifacts, including false 
positive IHC results in a truly HR negative tumor[20] or erroneously ER negative 
results in a truly ER positive tumor. It may also indicate the presence of tumor 
heterogeneity as a small PR positive subpopulation of cells within a larger both ER/PR 
negative tumor. In our study IHC ER/PR status defined by the routine analysis has been 
done on a fixed core needle biopsy, whereas the molecular profiling has been realized 
on another frozen samples by fine needle aspirations. Discordance form the distinct 
methods of the sampling and the possibilities false positive or negative results may be 
inevitable.[21] mRNA based methods to assess hormone receptor status may help 
resolve some of these uncertainties.[22] We assessed gene expression profiling data in 
501 primary breast cancer to find out how often ER negative/PR positive patients by 
IHC showed molecular features of ER positive disease.  
The minority (25%) of ER negative/PR positive tumors and the majority (79%) 
of ER positive/PR negative tumors showed ER positive status by ESR1 mRNA gene 
expression data and had high expression of ER related genes. Five of twenty patients 
with ER negative/PR positive cancers by IHC were ER positive by ESR1 mRNA and 
ER metagene expression. Four of these 5 cancers were also classified as luminal 
subtypes by the PAM50 classifier and therefore likely represent false negative ER IHC 
results. On the other hand, 15 of the 20 ER negative/PR positive cancers showed low 
ESR1 mRNA and ER metagene expression and all of these cancers were classified as 
non-luminal subtypes by a PAM50. This suggests that the majority of ER negative but 
PR positive cancers may not be endocrine sensitive. However the mRNA measurements 
represent bulk expression results for heterogeneous tissue. It is possible that small truly 
PR positive and endocrine sensitive subpopulation of cells may exist within a larger 
ER/PR negative tumor and signal from these cells is not apparent in the global 
expression data from the whole tissue.[11, 23, 24]    
In these series, twenty ER negative/PR positive patients who received 
chemotherapy (and about half of them received additional adjuvant hormone therapy) 
have equivalent prognosis to ER/PR positive or ER positive/PR negative that received 
both chemo and hormone therapies. Overall, the expected benefit from hormone therapy 
is small in ER negative/PR positive tumors because majority of these tumors tend to be 
ER negative by ESR1 mRNA (75%), show low predicted hormone sensitivity by the 
SET gene signature (90%), and are predominantly non-luminal class (85%). On the 
other hand 60% of the ER negative/PR positive cancers were predicted to have high 
chemotherapy sensitivity by the DLDA30 predictor. 
This study has limitations. The number of ER negative/PR positive patients in 
this analysis is low. No prior study examined the molecular features of this rare disease 
subset and this study has the advantage of using centrally reviewed IHC results and a 
uniformly performed gene expression analysis. The molecular analysis yielded 
generally consistent results for different RNA-based methods to assess ER status, and 
hormone and chemotherapy sensitivities. Another limitation should be that gene 
expression analysis does not necessarily imply protein expression. Elevated mRNA may 
not be indicative of elevated protein expression. Therefore, the potential false positive 
that can be obtained through IHC, there is equaling uncertainty on whether the mRNA 
levels in these samples translates to protein expression. The uneven samples size for the 
four ER/PR subgroups, different types of adjuvant hormone therapy used, and different 
TNM stages across cohorts limit the interpretation of the survival analysis.       
In summary, only 20-25% of the ER negative/PR positive tumors show 
molecular features of ER positive cancers (i.e high ER mRNA expression, luminal 
molecular class). These cancers also have higher proliferation rate than ER positive 
cancers, higher predicted chemotherapy sensitivity and lower predicted hormone 
sensitivity. We concluded that in this rare subset of patients (i) a second RNA based 
assessment may help identifying the minority of ESR1 mRNA-positive, luminal type 
cancers and (ii) due to the substantial uncertainty about endocrine sensitivity and high 
chemotherapy sensitivity in this IHC ER negative/PR positive cancer population, the 
safest clinical approach may be to consider both adjuvant endocrine and chemotherapy. 
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Figure legends (2 Tables and 2 figures) 
Fig. 1 ESR1, Progesterone receptor (PR), ER metagene and MKI67 mRNA gene 
expression in four distinct immunosittochemistry (IHC) groups.  IHC groups were 
defined by the percentage of cells of that were positive of nuclear ER and PR staining.  
(A) Expression distribution of ESR1 mRNA.  (B) Expression distribution of PR 
mRNA.  (C) ER-related genes refers to the average expression of 4 probe sets that are 
highly coexpressed with ESR1.[25]  (D) Expression distribution of MKI67 mRNA.  P 
values were calculated with the Wilcoxon test.  
 
Fig. 2 Kaplan-Meier relapse free survival curves by estrogen receptor (ER) 
/progesterone receptor (PR) immunohistochemistry status.  Immunohistochemistry 
groups were defined by the percentage of ER/PR positive cells. P: Positive; N: 
Negative;  HR: Hazard ratio;  CI: Confidential interval. 
  
   
No of Pt. (%) 501
Age
Average 49.8
(mini.-max) (24 - 75)
ER by IHC
Positive/Negative 296 (59.1)/ 205(40.1)
PR by IHC
Positive/Negative 243(48.5) / 258(51.5)
HER2 by IHC and/or FISH
Positive/Negative 6 (1.2)/ 483(96.4)
NA 12(2.4)
T
0-2/3-4 284(56.7) / 217(43.3)
N
Positive/Negative 155(30.9) / 346(69.1)
Grade
I / II / III 31(6.2)/ 178(35.5) / 256(51.1)
NA 36(7.2)
* ER: Estrogen receptor; PR: Progesterone receptor; HER2:
Human epidermal growth factor receptor 2; T: Clinical tumor
size; N: Clinical lymph node status; NA: Not available.
Table 1 Patient characterisctics*
 223 44.5% 73 14.6% 20 4.0% 185 36.9%
Positive 213 95.5% 58 79.5% 5 25.0% 22 11.9%
Negative 10 4.5% 15 20.5% 15 75.0% 163 88.1%
LumA 131 58.7% 21 28.8% 3 15.0% 2 1.1%
LumB 51 22.9% 22 30.1% 1 5.0% 4 2.2%
Her2 12 5.4% 7 9.6% 2 10.0% 15 8.1%
Basal 13 5.8% 13 17.8% 13 65.0% 147 79.5%
Normal 16 7.2% 10 13.7% 1 5.0% 17 9.2%
High 21 9.4% 0 0.0% 1 5.0% 1 0.5%
Intermediate 33 14.8% 3 4.1% 1 5.0% 3 1.6%
Low 169 75.8% 70 95.9% 18 90.0% 181 97.8%
pCR 12 5.4% 15 20.5% 12 60.0% 154 83.2%
RD 211 94.6% 58 79.5% 8 40.0% 31 16.8%
Pos/Pos Pos/Neg Neg/Pos Neg/Neg
*ER: Estrogen receptor; PR: Progesterone receptor; Pos: sitive; Neg: Negative; GE: Gene expression; SET index: Symmans
et al 2010 JCO; DLDA30; Lee et al 2010 CCR; pCR: Pathological complete response; RD: Residual disease;
DLDA30
Table 2 Breast cancer subtypes and Genomic markers*
ER / PR by IHC
No of Pt. (%)
ER by GE
SET index
Molecular
subtypes
